2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Uterine Cervical Neoplasms
12
Papillomavirus Infections
11
Neoplasms
10
Breast Neoplasms
9
Uterine Cervical Dysplasia
7
Persistent Infection
5
Condylomata Acuminata
5
Prostatic Neoplasms
4
Melanoma
4
Anus Neoplasms
4
Vulvar Neoplasms
3
Lung Neoplasms
3
Herpes Zoster
3
Glioblastoma
3
Carcinoma, Non-Small-Cell Lung
3
Vaginal Neoplasms
2
Sarcoma
2
Neuroblastoma
2
Neoplasm Metastasis
2
Influenza, Human
2
HIV Infections
2
Glioma
2
Colonic Neoplasms
2
Breast Neoplasms, Male
2
Wilms Tumor
1
Whooping Cough
1
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Tetanus
1
Squamous Cell Carcinoma of Head and Neck
1
Interventions
Cyclophosphamide
87
fludarabine
77
fludarabine phosphate
45
Tacrolimus
45
Whole-Body Irradiation
42
Mycophenolic Acid
42
Busulfan
35
Melphalan
32
Antilymphocyte Serum
24
Methotrexate
23
thymoglobulin
22
Standard of Care
22
Rituximab
22
venetoclax
20
Thiotepa
20
Sirolimus
20
Azacitidine
20
Stem Cell Transplantation
18
Granulocyte Colony-Stimulating Factor
18
Practice Guidelines as Topic
17
Cytarabine
16
Bortezomib
16
Nivolumab
15
Filgrastim
15
Specimen Handling
14
Dexamethasone
14
Blood Specimen Collection
14
Cyclosporine
13
Surveys and Questionnaires
12
Mesna
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
Vaccines
×
Clear all
NCT01254630
2019-09-30
V212-011
Merck Sharp & Dohme LLC
Phase 3
Completed
5,305 enrolled
20 charts